Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,662Revenue $M0.5Net Margin (%)-26,074.0Z-Score50.4
Enterprise Value $M3,457EPS $-0.9Operating Margin %-26,379.5F-Score3
P/E(ttm))0Cash Flow Per Share $-0.5Pre-tax Margin (%)-26,091.7Higher ROA y-yY
Price/Book19.910-y EBITDA Growth Rate %-0.9Quick Ratio9.7Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %-8.9Current Ratio9.7Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-86.7Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-115.4Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M151ROI % (ttm)-74.8Gross Margin Increase y-yY

Gurus Latest Trades with IDIX

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
IDIXSeth Klarman 2014-03-31 Add2.25%$5.82 - $8.04
($6.96)
$ 24.28249%Add 44.49%53,331,109
IDIXSeth Klarman 2013-12-31 Add1.24%$3.29 - $6.93
($4.6)
$ 24.28428%Add 24.42%36,910,868
IDIXSeth Klarman 2013-09-30 Add0.43%$3.22 - $5.75
($4.38)
$ 24.28454%Add 10.83%29,665,693
IDIXSeth Klarman 2013-03-31 Add0.61%$3.54 - $5.36
($4.6)
$ 24.28428%Add 25.78%26,042,000
IDIXJohn Burbank 2013-03-31 Sold Out -0.19%$3.54 - $5.36
($4.6)
$ 24.28428%Sold Out0
IDIXSeth Klarman 2012-12-31 Add1.35%$3.52 - $5.3
($4.51)
$ 24.28438%Add 72.54%20,704,700
IDIXJean-Marie Eveillard 2012-12-31 Sold Out -0.0025%$3.52 - $5.3
($4.51)
$ 24.28438%Sold Out0
IDIXSeth Klarman 2012-09-30 Add0.28%$4.39 - $11.06
($7.89)
$ 24.28208%Add 20%12,000,000
IDIXJean-Marie Eveillard 2012-09-30 Buy $4.39 - $11.06
($7.89)
$ 24.28208%New holding, 150000 sh.150,000
IDIXSeth Klarman 2012-06-30 Add0.47%$7.24 - $10.71
($8.92)
$ 24.28172%Add 21.23%10,000,000
IDIXJohn Burbank 2012-06-30 Add0.26%$7.24 - $10.71
($8.92)
$ 24.28172%Add 150%1,250,000
IDIXSeth Klarman 2012-03-31 Add0.85%$7.01 - $14.89
($11.02)
$ 24.28120%Add 45.61%8,249,000
IDIXJohn Burbank 2012-03-31 Buy 0.17%$7.01 - $14.89
($11.02)
$ 24.28120%New holding, 500000 sh.500,000
IDIXGeorge Soros 2012-03-31 Sold Out -0.08%$7.01 - $14.89
($11.02)
$ 24.28120%Sold Out0
IDIXSeth Klarman 2011-12-31 Add0.73%$4.55 - $8.22
($6.49)
$ 24.28274%Add 126.6%5,665,000
IDIXGeorge Soros 2011-12-31 Add0.08%$4.55 - $8.22
($6.49)
$ 24.28274%Add 1382.72%255,028
IDIXSeth Klarman 2011-09-30 Add0.21%$4.15 - $6.96
($5.68)
$ 24.28328%Add 99.09%2,500,000
IDIXGeorge Soros 2011-09-30 Buy $4.15 - $6.96
($5.68)
$ 24.28328%New holding, 17200 sh.17,200
IDIXSeth Klarman 2011-06-30 Buy 0.26%$2.9 - $5.3
($4.65)
$ 24.28422%New holding, 1255700 sh.1,255,700
IDIXJean-Marie Eveillard 2010-03-31 Sold Out -0.01%$2.12 - $3.06
($2.78)
$ 24.28773%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

IDIX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
IDIX Seth Klarman 2014-03-3153,331,10935.367.3+44.49%
Premium Most recent portfolio changes are included for Premium Members only!


IDIX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BAUPOST GROUP LLC/MA10% Owner 2014-01-31Buy16,420,241$6.5270.15view
Fanning PaulSVP, Human Resources 2012-03-16Sell30,000$11.04117.93view
NOVARTIS AG 2011-02-25Buy3,723$3.71548.52view
NOVARTIS AG 2010-11-26Buy1,983$5.09372.69view
NOVARTIS AG 2010-08-13Buy37,214$2.45882.04view
HODGSON THOMAS RDirector 2009-12-16Buy25,387$2.141024.3view
HODGSON THOMAS RDirector 2009-12-14Buy24,613$2.091051.2view
Weidenbruch JohnEx. VP, Gen. Counsel and Secr. 2009-11-24Buy20,000$1.891173.02view
NOVARTIS AG10% Owner 2006-06-06Buy365$20.4817.48view
NOVARTIS AG10% Owner 2006-04-04Buy2,938$16.2348.24view

Press Releases about IDIX :

    Quarterly/Annual Reports about IDIX:

    News about IDIX:

    Articles On GuruFocus.com
    Seth Klarman Tops Guru Scoreboard for First Half 2014 Jul 05 2014 
    The Peril of Being a Copycat Jun 26 2014 
    Seth Klarman Buys Cheniere Energy, Keryx Biopharmaceuticals, Idenix Pharmaceuticals, Sells BP, Fidel May 15 2014 
    Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
    2013 - Mistakes of Commission,Omission & Confusion Feb 12 2014 
    Seth Klarman Buys Micron Technology, Theravance, PBF Energy, Sells BP, AIG, Yamana Gold Nov 13 2013 
    Seth Klarman Continues Aggressively Buying Drug Company, Soros Adds Mercury Systems Nov 05 2013 
    The Philosophy and Value of Gurufocus Sep 08 2013 
    Seth Klarman Buys BP, AIG, Elan Corp, Sells News Corp., Oracle May 14 2013 
    valuation May 12 2013 

    More From Other Websites
    [video] Cramer's Stop Trading: Yellen effect Jul 16 2014
    A Pre-Earnings Update On Gilead Jul 10 2014
    Seth Klarman Is Top-Performing Guru for First Half 2014 Jul 05 2014
    A Primer On The Hepatitis C Market Jul 03 2014
    Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline Jul 03 2014
    Idenix (IDIX) is in Overbought Territory: What's Next? Jul 03 2014
    What If Legacy Pharmaceutical And Consumer Business Keeps Falling For Merck? Jun 27 2014
    Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly Jun 27 2014
    Keryx Biopharmaceuticals: Baupost Group's New Position Suggests A Possible Takeout And 100%+ Gains Jun 24 2014
    Market Wrap For June 20: Yet Again, Dow And S&P 500 Indices Hit New Highs Jun 20 2014
    [video] 3 Reasons for Russell 2000 surge Jun 20 2014
    Achillion Could Win Idenix's Mystery Suitor: Analyst Jun 20 2014
    Speculators On The Next HCV Acquisition Should Not Overlook Technological Platforms Jun 20 2014
    Idenix received bid above $18.00 per share prior to deal with Merck Jun 20 2014
    Merck begins tender offer to acquire Idenix Jun 20 2014
    Idenix Pharmaceuticals Cut to Neutral from Buy at UBS Jun 19 2014
    The Zacks Analyst Blog Highlights: Idenix, Achillion Pharmaceuticals, Nektar, Orexigen, Celgene,... Jun 19 2014
    Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar Jun 18 2014
    IDENIX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 17 2014

    Add Notes, Comments or Ask Questions

    User Comments

    Bradlewski
    ReplyBradlewski - 1 week ago
    Merck is buying it for $24.5/share.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide